Sandoz EMA Trastuzumab Application Follows US Filing
European Filing For Herceptin Biosimilar Comes Shortly After FDA Submission
Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.
You may also be interested in...
Sandoz looks to be in line for an EU-wide approval for its trastuzumab biosimilar during 2023, with the backing of the EMA’s Committee for Medicinal Products for Human Use.
Sandoz spoke to Generics Bulletin in the wake of confirming a recent complete response letter for its partnered biosimilar Herceptin candidate in the US.
Novartis admits that its Sandoz division is not expected to enjoy turnover growth in 2022, due to a lack of material launches, but is planning for a rise in 2023 and beyond.